DE69528894T2 - Bifunktionelles protein, herstellung und verwendung - Google Patents
Bifunktionelles protein, herstellung und verwendungInfo
- Publication number
- DE69528894T2 DE69528894T2 DE69528894T DE69528894T DE69528894T2 DE 69528894 T2 DE69528894 T2 DE 69528894T2 DE 69528894 T DE69528894 T DE 69528894T DE 69528894 T DE69528894 T DE 69528894T DE 69528894 T2 DE69528894 T2 DE 69528894T2
- Authority
- DE
- Germany
- Prior art keywords
- sub
- hinge region
- zeta
- bifunctional protein
- joined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001588 bifunctional effect Effects 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94810244 | 1994-05-02 | ||
PCT/EP1995/001494 WO1995030014A1 (en) | 1994-05-02 | 1995-04-20 | Bifunctional protein, preparation and use |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69528894D1 DE69528894D1 (de) | 2003-01-02 |
DE69528894T2 true DE69528894T2 (de) | 2003-03-27 |
Family
ID=8218248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69528894T Expired - Lifetime DE69528894T2 (de) | 1994-05-02 | 1995-04-20 | Bifunktionelles protein, herstellung und verwendung |
Country Status (18)
Country | Link |
---|---|
US (1) | US6984382B1 (de) |
EP (1) | EP0758394B1 (de) |
JP (1) | JP3742103B2 (de) |
KR (1) | KR100373813B1 (de) |
AT (1) | ATE228166T1 (de) |
AU (1) | AU694222B2 (de) |
CA (1) | CA2188422C (de) |
DE (1) | DE69528894T2 (de) |
DK (1) | DK0758394T3 (de) |
ES (1) | ES2185705T3 (de) |
FI (1) | FI119191B (de) |
IL (1) | IL113530A0 (de) |
NO (1) | NO316923B1 (de) |
NZ (1) | NZ285395A (de) |
PT (1) | PT758394E (de) |
TW (1) | TW428026B (de) |
WO (1) | WO1995030014A1 (de) |
ZA (1) | ZA953440B (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2188422C (en) | 1994-05-02 | 2011-03-15 | Bernd Groner | Bifunctional protein, preparation and use |
EP0870040A2 (de) * | 1995-12-29 | 1998-10-14 | Chiron Corporation | Genabgabevehikel-zielgerichtete ligande |
WO1998012227A1 (en) * | 1996-09-19 | 1998-03-26 | Diagnocure Inc. | Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
DE10121113A1 (de) * | 2001-04-28 | 2002-10-31 | Gabriele Pecher | Genmodifizierte YT Zelllinie und ihre Verwendung |
PT2921500T (pt) | 2004-07-10 | 2023-09-25 | The Institute For Cancer Res | Linhas de células assassinas naturais humanas modificadas geneticamente |
US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
SI1912675T1 (sl) | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
MX363905B (es) * | 2006-06-12 | 2019-04-08 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
US20100105136A1 (en) * | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
EP2132228B1 (de) | 2008-04-11 | 2011-06-22 | Emergent Product Development Seattle, LLC | Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon |
WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
ES2602743T3 (es) | 2010-09-08 | 2017-02-22 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
CN106220739A (zh) | 2010-12-09 | 2016-12-14 | 宾夕法尼亚大学董事会 | 嵌合抗原受体‑修饰的t细胞治疗癌症的用途 |
US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
JP6389166B2 (ja) | 2012-05-07 | 2018-09-12 | トラスティーズ・オブ・ダートマス・カレッジ | 抗b7−h6抗体、融合タンパク質、及びこれらを使用する方法 |
CN111139256A (zh) | 2013-02-20 | 2020-05-12 | 诺华股份有限公司 | 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症 |
UY35340A (es) | 2013-02-20 | 2014-09-30 | Novartis Ag | Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123 |
US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
WO2015090230A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
IL293603B2 (en) | 2014-04-07 | 2024-03-01 | Novartis Ag | Cancer treatment using chimeric antigen receptor (CAR) against CD19 |
US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
TWI718992B (zh) | 2014-07-21 | 2021-02-21 | 瑞士商諾華公司 | 使用cll-1嵌合抗原受體治療癌症 |
JP7084138B2 (ja) | 2014-08-19 | 2022-06-14 | ノバルティス アーゲー | 癌処置に使用するための抗cd123キメラ抗原受容体(car) |
CA2961636A1 (en) | 2014-09-17 | 2016-03-24 | Boris ENGELS | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
CA2963935A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
US10273300B2 (en) | 2014-12-29 | 2019-04-30 | The Trustees Of The University Of Pennsylvania | Methods of making chimeric antigen receptor-expressing cells |
WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
RU2021121771A (ru) | 2015-04-08 | 2022-01-12 | Новартис Аг | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19 |
WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
AU2016297014B2 (en) | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
EP3331913A1 (de) | 2015-08-07 | 2018-06-13 | Novartis AG | Behandlung von krebs mithilfe von chimären cd3-rezeptor-proteinen |
US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
EP3393504A1 (de) | 2015-12-22 | 2018-10-31 | Novartis AG | Chimärer antigenrezeptor (car) gegen mesothelin und antikörper gegen pd-l1-hemmer zur kombinierten verwendung in der krebstherapie |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
EP4043485A1 (de) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie |
WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
CA3054621A1 (en) | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
EP3806962A1 (de) | 2018-06-13 | 2021-04-21 | Novartis AG | Bcma-chimäre antigenrezeptoren und verwendungen davon |
CN110627895B (zh) * | 2018-06-25 | 2021-03-23 | 北京大学 | 肺癌特异性tcr及其分析技术和应用 |
AU2019328677A1 (en) | 2018-08-31 | 2021-04-01 | Invectys SA | Chimeric antigen receptors against multiple HLA-G isoforms |
US11975026B2 (en) | 2019-11-26 | 2024-05-07 | Novartis Ag | CD19 and CD22 chimeric antigen receptors and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0260880A3 (de) | 1986-09-11 | 1990-03-07 | Dana-Farber Cancer Institute, Inc. | Verfahren zur Auslösung der Zytotoxizität |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
FI105320B (fi) | 1988-04-04 | 2000-07-31 | Oncogen | Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa |
DK0568537T3 (da) | 1990-10-31 | 1998-09-23 | Whitehead Biomedical Inst | Genetisk modificering af endotelceller |
DE69123241T2 (de) * | 1990-12-14 | 1997-04-17 | Cell Genesys Inc | Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen |
AU662311B2 (en) * | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
FR2672901B1 (fr) | 1991-02-15 | 1994-09-30 | Immunotech Sa | Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant. |
WO1992015326A1 (en) | 1991-02-27 | 1992-09-17 | The Regents Of The University Of California | Targeting complex mediated immunogenicity |
IE920716A1 (en) | 1991-03-07 | 1992-09-09 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
US5939531A (en) | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
WO1993019163A1 (en) * | 1992-03-18 | 1993-09-30 | Yeda Research And Development Co, Ltd. | Chimeric receptor genes and cells transformed therewith |
WO1993020840A1 (en) | 1992-04-14 | 1993-10-28 | British Bio-Technology Limited | Induction of ctl responses |
CA2188422C (en) | 1994-05-02 | 2011-03-15 | Bernd Groner | Bifunctional protein, preparation and use |
-
1995
- 1995-04-20 CA CA2188422A patent/CA2188422C/en not_active Expired - Lifetime
- 1995-04-20 WO PCT/EP1995/001494 patent/WO1995030014A1/en active IP Right Grant
- 1995-04-20 DE DE69528894T patent/DE69528894T2/de not_active Expired - Lifetime
- 1995-04-20 ES ES95918576T patent/ES2185705T3/es not_active Expired - Lifetime
- 1995-04-20 DK DK95918576T patent/DK0758394T3/da active
- 1995-04-20 PT PT95918576T patent/PT758394E/pt unknown
- 1995-04-20 NZ NZ285395A patent/NZ285395A/xx not_active IP Right Cessation
- 1995-04-20 KR KR1019960706165A patent/KR100373813B1/ko not_active IP Right Cessation
- 1995-04-20 EP EP95918576A patent/EP0758394B1/de not_active Expired - Lifetime
- 1995-04-20 JP JP52796595A patent/JP3742103B2/ja not_active Expired - Fee Related
- 1995-04-20 AU AU24469/95A patent/AU694222B2/en not_active Ceased
- 1995-04-20 AT AT95918576T patent/ATE228166T1/de active
- 1995-04-24 TW TW084103999A patent/TW428026B/zh active
- 1995-04-28 ZA ZA953440A patent/ZA953440B/xx unknown
- 1995-04-28 IL IL11353095A patent/IL113530A0/xx not_active IP Right Cessation
-
1996
- 1996-10-25 FI FI964311A patent/FI119191B/fi not_active IP Right Cessation
- 1996-11-01 NO NO19964641A patent/NO316923B1/no not_active IP Right Cessation
-
2000
- 2000-06-19 US US09/596,774 patent/US6984382B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NO964641D0 (no) | 1996-11-01 |
FI119191B (fi) | 2008-08-29 |
AU2446995A (en) | 1995-11-29 |
WO1995030014A1 (en) | 1995-11-09 |
US6984382B1 (en) | 2006-01-10 |
ZA953440B (en) | 1995-11-02 |
NO964641L (no) | 1996-11-01 |
DK0758394T3 (da) | 2003-03-03 |
NO316923B1 (no) | 2004-06-28 |
CA2188422A1 (en) | 1995-11-09 |
ES2185705T3 (es) | 2003-05-01 |
JPH09512176A (ja) | 1997-12-09 |
EP0758394A1 (de) | 1997-02-19 |
AU694222B2 (en) | 1998-07-16 |
NZ285395A (en) | 1998-10-28 |
PT758394E (pt) | 2003-04-30 |
KR100373813B1 (ko) | 2003-10-08 |
JP3742103B2 (ja) | 2006-02-01 |
CA2188422C (en) | 2011-03-15 |
FI964311A (fi) | 1996-10-25 |
TW428026B (en) | 2001-04-01 |
EP0758394B1 (de) | 2002-11-20 |
FI964311A0 (fi) | 1996-10-25 |
DE69528894D1 (de) | 2003-01-02 |
IL113530A0 (en) | 1995-07-31 |
ATE228166T1 (de) | 2002-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69528894T2 (de) | Bifunktionelles protein, herstellung und verwendung | |
NO963018L (no) | CTLA4-mutantmolekyler og anvendelser derav | |
ES2093623T3 (es) | Receptores monovalentes y oligovalentes, bioespecificos y oligoespecificos, su preparacion y empleo. | |
NO934801D0 (no) | CTL4A reseptor, fusjonsproteiner som inneholder den og anvendelse derav | |
WO2000023573A3 (en) | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies | |
KR927003847A (ko) | 수용체-결합된 신호 변환 경로를 위한 키메라 사슬 | |
EP1878746A3 (de) | Humane monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor | |
WO2002077029A3 (en) | Cd19-specific redirected immune cells | |
GR3030415T3 (en) | Platelet activating factor antagonists. | |
IL112390A0 (en) | A cell which expresses chimeric receptors, DNA and vectors encoding said receptors and pharmaceutical compositions containing the same | |
EP0325262A3 (en) | Cloned genes encoding ig-cd4 fusion proteins and the use thereof | |
CA2195653A1 (en) | Cells bearing cd4 decoy receptors and related molecules and methods | |
WO1996021028A3 (en) | Soluble heterodimeric t cell receptors and their antibodies | |
WO1999042127A3 (en) | Receptor derived peptides as modulators of receptor activity | |
AU5173996A (en) | Methadone derivatives and protein and polypeptide methadone derivative conjugates and labels | |
DE69631624D1 (de) | Antikörper gegen menschliches restrictin | |
AU3283693A (en) | Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy | |
NO940797L (no) | Reseptorderivater som har bindingseter for human-rhinovirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |